Photoimmunotherapy Targeting Esophagogastric Junction Adenocarcinoma With Fully Human Anti-Epcam Antibody

Puntos clave

• Improved targeting of adenocarcinoma was noted, highlighting the potential of photoimmunotherapy to enhance treatment outcomes.
• Anti-EPCAM antibody shows promise in effectively targeting esophagogastric junction tumors, with implications for clinical applications.
• Analysis focuses on the role of photoimmunotherapy in treating specific cancer types, particularly adenocarcinoma.
• The findings underscore the need for further evaluation of this therapy in larger trials and broader populations.